GeneReach Biotechnology Corp.
4171
Rank in Stocks
#25430
GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes... GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes in the development, production, and commercialization of advanced nucleic acid detection technologies. The company's extensive product line features essential laboratory instrumentation, including automated nucleic acid extraction systems, prep homogenization systems, and mini centrifuges. GeneReach also provides a wide range of reagents and consumables, such as human In Vitro Diagnostic (IVD) assays, specific iiPCR reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and various research-grade reagents and supplies. Beyond its product offerings, GeneReach delivers comprehensive services. These encompass polymerase chain reaction (PCR) training programs, expert molecular diagnostic technical solutions, laboratory installation assistance, OEM/ODM contract manufacturing capabilities, and collaborative research services. Its innovative solutions cater to a diverse clientele, with applications spanning aquaculture, agriculture, food safety, human health, and the welfare of companion animals and livestock. GeneReach Biotechnology Corp. was established in 2004.
Share Price
$0.45726688
Last synced: 2026-11-10
Market Cap
$26.00M
Change (1 day)
-0.99%
Change (1 year)
-35.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GeneReach Biotechnology Corp. (4171)
Category
Healthcare
Operating Margin for GeneReach Biotechnology Corp. (4171)
Operating Margin as of November 2026 TTM: -8.35%
According to GeneReach Biotechnology Corp.'s latest financial reports, its current operating margin (TTM) is -8.35%. At the end of 2025 the company had an operating margin of -34.31%.
Operating Margin history for GeneReach Biotechnology Corp. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -8.35% | -75.66% |
| 2025 | -34.31% | -46.01% |
| 2024 | -63.55% | -37.51% |
| 2023 | -101.70% | -374.49% |
| 2022 | 37.05% | -22.00% |
| 2021 | 47.50% | 18.07% |
| 2020 | 40.23% | 31.47% |
| 2019 | 30.60% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -104.62% |
US
|
|
| -149.01% | -82.15% |
US
|
|
| 25.57% | -103.06% |
AU
|
|
| 31.23% | -103.74% |
BE
|
|
| 29.35% | -103.51% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about GeneReach Biotechnology Corp.'s operating margin
What is GeneReach Biotechnology Corp.'s operating margin?
GeneReach Biotechnology Corp.'s operating margin is -8.35%, as of Nov 2026.
What was GeneReach Biotechnology Corp.'s operating margin in 2025?
In 2025, GeneReach Biotechnology Corp.'s operating margin was -34.31%, compared with -63.55% in 2024.
How has GeneReach Biotechnology Corp.'s operating margin changed since 2020?
From 2020 to 2025, GeneReach Biotechnology Corp.'s operating margin was highest in 2021 (47.50%) and lowest in 2023 (-101.70%).
How does GeneReach Biotechnology Corp.'s operating margin compare with similar companies?
GeneReach Biotechnology Corp.'s operating margin (-8.35%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.